<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807624</url>
  </required_header>
  <id_info>
    <org_study_id>SR 2-06</org_study_id>
    <nct_id>NCT01807624</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)</brief_title>
  <official_title>The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of The Highest Phase 3 Dose Of Kovacaine™ Mist To Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Renatus, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Triligent International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Analytical Bio-Chemistry Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Renatus, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics/pharmacodynamics and safety of&#xD;
      a nasal spray containing the anesthetic drug tetracaine in combination with oxymetazoline&#xD;
      with blood draws over 24 hours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics and safety of tetracaine,&#xD;
      para- butylaminobenzoic acid (PBBA), and oxymetazoline after intranasal administration of the&#xD;
      highest Phase 3 dose of Kovacaine Mist (Tetracaine Hydrochloride with Oxymetazoline&#xD;
      Hydrochloride) to healthy volunteers.&#xD;
&#xD;
      This is an open-label, single-treatment, single-dose study in healthy volunteers in which all&#xD;
      subjects will receive the highest Phase 3 dose of Kovacaine Mist on one occasion. No&#xD;
      randomization is necessary for this single treatment, single dose study. A single study&#xD;
      center will participate.&#xD;
&#xD;
      Each subject will receive a single dose of Kovacaine Mist (3% tetracaine HCl with 0.05%&#xD;
      oxymetazoline HCl) consisting of 3 sprays (each 0.2 mL) in one nostril not taking longer than&#xD;
      8 minutes, for a total 0.6 mL dose containing 18 mg tetracaine HCl and 0.3 mg oxymetazoline&#xD;
      HCl.&#xD;
&#xD;
      The total dosing period will be 8 minutes. Subjects will be required to fast 10 hours prior&#xD;
      to dosing and for four (4) hours after dosing. Water will be allowed ad lib during the study&#xD;
      except for one (1) hour prior through one (1) hour after dose administration. Subjects will&#xD;
      be admitted to the study unit no later than 2100 hours of the evening prior to drug&#xD;
      administration and will remain in the unit until the 24 hour blood sample is collected and&#xD;
      discharge procedures are completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity of Oxymetazoline and PBBA</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 Increase of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 Decrease of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Kovacaine Mist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine HCl 3% and Oxymetazoline HCl 0.05%</intervention_name>
    <description>1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)</description>
    <arm_group_label>Kovacaine Mist</arm_group_label>
    <other_name>Kovacaine Nasal Spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-breast-feeding female subjects between the ages of 18 and 75&#xD;
             years (inclusive).&#xD;
&#xD;
          -  Can understand and sign the informed consent document, can communicate with the&#xD;
             investigator, and can understand and comply with the requirements of the protocol.&#xD;
&#xD;
          -  Body mass index between 18 and 35 BMI.&#xD;
&#xD;
          -  Sufficiently healthy as determined by the investigator to receive the test medications&#xD;
             and undergo the scheduled study procedure.&#xD;
&#xD;
          -  Can breathe through both nostrils.&#xD;
&#xD;
          -  Screening BP ≤ 140/90 mm Hg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant respiratory, gastrointestinal, renal, hepatic,&#xD;
             neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or&#xD;
             cardiovascular disease, including cardiac arrhythmia, narrow angle glaucoma and benign&#xD;
             prostatic hypertrophy (in men), uncontrolled thyroid disease (including Hashimoto's&#xD;
             Thyroiditis and lymphocytic thyroiditis), uncontrolled diabetes mellitus or any other&#xD;
             condition which, in the opinion of the Principal Investigator, would jeopardize the&#xD;
             safety of the subject or impact the validity of the study results.&#xD;
&#xD;
          -  Has clinically significant abnormal findings on the physical examination, medical&#xD;
             history, electrocardiogram (ECG), or clinical laboratory evaluation during screening.&#xD;
             This includes current upper respiratory infections.&#xD;
&#xD;
          -  Currently experiencing seasonal or perennial allergic rhinitis, recurrent nose-bleeds&#xD;
             or asthma, or has a significant history of these conditions, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Current, including the last 30 days, sinusitis or other upper respiratory infections.&#xD;
&#xD;
          -  Nasal polyps, significant nasal or sinus surgery or other abnormality that may&#xD;
             interfere with the dose administration.&#xD;
&#xD;
          -  History of allergic or adverse responses to tetracaine, other ester local anesthetics,&#xD;
             PBBA, oxymetazoline and its preservatives, or para-aminobenzoic acid as found in PABA&#xD;
             containing sunscreens or any comparable or similar product.&#xD;
&#xD;
          -  Donation of blood or plasma within 30 days of the first dose of Study Drug.&#xD;
&#xD;
          -  Participation in a clinical trial within 30 days prior to the first dose of Study&#xD;
             Drug.&#xD;
&#xD;
          -  Use of any new over-the-counter (OTC) medication, including topical anesthetic creams&#xD;
             or gels, vitamins, within seven days prior to the first dose of the Study Drug or&#xD;
             during the study unless approved by the Principal Investigator.&#xD;
&#xD;
          -  Any prescription medication, whose dose is not stable at the time of screening, as&#xD;
             determined by the Principal Investigator.&#xD;
&#xD;
          -  Treatment with any known enzyme altering drugs such as barbiturates, phenothiazines,&#xD;
             cimetidine, carbamazepine, etc., within 30 days prior to the first dose of Study Drug&#xD;
             or during the study.&#xD;
&#xD;
          -  Smoking or use of tobacco products within 6 months prior to the first dose of Study&#xD;
             Drug or during the study.&#xD;
&#xD;
          -  Female trying to conceive, is pregnant, suspected of being pregnant, or is lactating.&#xD;
             (Females of child-bearing potential will be required to take a serum pregnancy test at&#xD;
             screening (up to 21 days prior to the start of the study, including the day of the&#xD;
             study), as well as a urine pregnancy test at check-in to rule out pregnancy.)&#xD;
&#xD;
          -  Positive serum pregnancy test at screening or urine pregnancy test at check-in for all&#xD;
             women of childbearing potential.&#xD;
&#xD;
          -  Positive blood screen for HIV, Hepatitis B surface antigen (HbSAg), or Hepatitis C, or&#xD;
             a positive urine screen for alcohol, drugs of abuse, or cotinine.&#xD;
&#xD;
          -  Have a history of pseudocholinesterase deficiency or previous prolonged paralysis with&#xD;
             succinylcholine or difficulty waking up from general anesthesia.&#xD;
&#xD;
          -  Have a history of alcoholism and/or drug abuse.&#xD;
&#xD;
          -  Have taken a monoamine oxidase inhibitor or vasopressor drug within the past 3 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Mulvahill</last_name>
    <role>Study Chair</role>
    <affiliation>St. Renatus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>November 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <disposition_first_submitted>May 15, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 15, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 8, 2015</disposition_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Kovacaine Nasal Spray</title>
          <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kovacaine Nasal Spray</title>
          <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Oxymetazoline and PBBA</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465" spread="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Oxymetazoline and PBBA</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life of Oxymetazoline and PBBA</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Oxymetazoline and PBBA</title>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="960" spread="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-infinity of Oxymetazoline and PBBA</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity of Oxymetazoline and PBBA</title>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxymetazoline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBBA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="973" spread="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in SBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in DBP &gt; 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Pulse Rate &gt; 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2 Increase of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2 Increase of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2 Decrease of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
        <time_frame>0, 5, 10, 15, 20, 25, 30, 40, 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours after completion of the last nasal spray</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2 Decrease of &gt; 5% on 2 Consecutive Measurements After Administration of Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kovacaine Nasal Spray</title>
          <description>Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure&#xD;
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Runny nose</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngeal Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Derek Muse</name_or_title>
      <organization>Jean Brown Research Center</organization>
      <phone>(801) 261-2000</phone>
      <email>participate@jeanbrownresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

